Summary & Overview
HCPCS J9199: Gemcitabine Hydrochloride Injection, 200 mg
HCPCS Level II code J9199 denotes the 200 mg unit of gemcitabine hydrochloride (Infugem), a widely used cytotoxic chemotherapy agent. As a unit-based drug code, J9199 is used to bill the medication itself separate from the infusion or administration procedure, making it a key element in oncology drug reimbursement and cost reporting nationally. The code matters because gemcitabine is commonly administered across outpatient oncology settings and contributes materially to drug spend and pathway-level cost management.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, the typical settings where the drug is billed, and the national context for its use. The publication summarizes common benchmarks for unit pricing and utilization patterns, highlights policy and reimbursement considerations affecting oncology drug billing, and provides clinical context on gemcitabine as a treatment agent. Where available, the report presents comparative payer coverage notes and standard billing practices associated with unit-based chemotherapy drug coding. Data not available in the input is noted where relevant.
Billing Code Overview
HCPCS Level II code J9199 represents an injection of gemcitabine hydrochloride (Infugem), 200 mg. This code describes a chemotherapy drug administration as a billed drug unit rather than the infusion procedure itself.
-
Service type: Chemotherapy drug administration (unit-based drug billing)
-
Typical site of service: Hospital outpatient infusion center, physician office infusion suite, or ambulatory infusion center
Data not available in the input for payers, common modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A 62-year-old female with metastatic pancreatic adenocarcinoma presents to the outpatient oncology infusion center for systemic chemotherapy. The treatment plan includes single-agent gemcitabine hydrochloride administered intravenously. Pre-treatment workflow includes nursing assessment (vital signs, weight, review of labs including CBC and CMP), verification of chemotherapy order by the oncologist and pharmacist, preparation of J9199 (gemcitabine hydrochloride, 200 mg vial) in an appropriate sterile compounding area, and patient informed consent already documented in the chart. On the day of service the patient is admitted to the ambulatory infusion chair; nursing confirms venous access (peripheral IV or implanted port), performs time-out, administers antiemetic per protocol if needed, and initiates the gemcitabine infusion at the ordered dose and rate. Post-infusion monitoring includes observation for infusion reactions, documentation of administered lot numbers and vial counts, and billing capture of the number of J9199 units used based on the total milligrams administered. Typical sites of service for this procedure are the hospital outpatient infusion center, freestanding oncology clinic infusion suite, or physician office infusion room. The clinician and pharmacist coordinate scheduling, prior authorization (if required by payors such as Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, BUCA, Medicare), and documentation of chemotherapy regimen and cycle number in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|